TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.

The presentations include:

• Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
• Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
• Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human Tissues

All presentations will take place in the Exhibit Halls AB at the George R. Brown Convention Center. The presentation materials will be available on TScan's website after the event concludes.

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39^th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.

Poster Presentation Details:

Title: Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
Authors: Rutuja Kulkarni, Akshat Sharma, Vivin Karthik, Kenneth L Jahan, Rakshi Bala, Nicolas Gaspar, Amanda Kordosky, Daniel C Pollacksmith, Alok Das Mahopatra, Maytal Bowman, Drashti Shah, Victor Ospina, Sanket Shah, Skyler Martinez, Ryan E Kritzer, Jayanth Jawahar, Hana Husic, Shoshana Bloom, Emily Miga, Rachel Lent, Chandan K Pavuluri, Carolyn Hardy, Abigail Dooley, Alex Cristofaro, Zhonghua Zhu, Livio Dukaj, Antoine Boudot, Kimberly M Cirelli, Mollie M Jurewicz, Cagan Gurer
Abstract Number: 375
Session Date/Time: Friday, November 8; 9:00 a.m. - 7:00 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center

Title: Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
Authors: Maytal Bowman, Amanda Kordosky, Daniel Pollacksmith, Alok Das Mohapatra, Debanjan Goswamy, Victor Ospina, Sanket Revadkar, Shubhangi Kamalia, Skyler Martinez, Gaenna Rogers, Teagan Parsons, Dalena Nguyen, Jenny Tadros, Ira Jain, Alexander Cristofaro, Jenna LaBelle, Ribhu Nayar, Nancy Nabilsi, Antoine Boudot
Abstract Number: 359
Session Date/Time: Friday, November 8; 9:00 a.m. - 7:00 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center

Title: Development of a Target Agnostic Platform to Assess the Reactivity of T Cell Receptor (TCR)-Engineered T Cell (TCR-T) Therapies to Primary Human Tissues
Authors: Sveta Padmanabhan, Shubhangi Kamalia, Drashti Shah, Shazad A Khokhar, Sadie Lee, Daniel C Pollacksmith, Kimberly M Cirelli, Vivin Karthik, Kenneth Jahan, Jenny Tadros, Teagan Parsons, Nancy Nabilsi, Andrew Ferretti, Dalena Nguyen, Livio Dukaj, Jin He, Ryan E Kritzer, Emily Miga, Alexander Cristofaro, Chandan K Pavuluri, Elisaveta Todorova, Tyler M Sinacola, Savannah G Szemethy, Kyra N Sur, Vandana Keskar, Carolyn Hardy, Hsin-Ho Huang, Zhonghua Zhu, Antoine J Boudot, Sonal Jangalwe, Ribhu Nayar, Gavin MacBeath
Abstract Number: 384
Session Date/Time: Saturday, November 9; 9:00 a.m. - 8:30 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center
                                
A copy of the presentation materials will be added to the “Publications” section of the Company’s website at tscan.com once presentations have concluded.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^TM Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com   

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

What is TScan Therapeutics presenting at the SITC 39th Annual Meeting?

TScan Therapeutics (TCRX) is presenting three poster abstracts at the SITC 39th Annual Meeting, focusing on their TCR-T therapies for cancer treatment, including a MAGE-A4-specific therapy, T-Plex for addressing tumor heterogeneity, and a platform to assess TCR-T therapy reactivity.

When and where is the SITC 39th Annual Meeting taking place?

The SITC 39th Annual Meeting is being held from November 6-10, 2024, in Houston, TX and virtually. The poster presentations will be displayed in the Exhibit Halls AB at the George R. Brown Convention Center.

What is the focus of TScan Therapeutics' (TCRX) research?

TScan Therapeutics (TCRX) is focused on developing T cell receptor (TCR)-engineered T cell therapies for the treatment of patients with cancer. Their research includes multiplex treatments for solid tumors and addressing intra-tumor antigen and HLA heterogeneity.

How can investors access TScan Therapeutics' (TCRX) presentation materials from the SITC meeting?

TScan Therapeutics (TCRX) will add a copy of the presentation materials to the 'Publications' section of their company website at tscan.com once the presentations have concluded at the SITC 39th Annual Meeting.